Investigating the impact of psychedelic drugs on social cognition defects: A scoping review protocol.

A scoping review protocol describes a plan to systematically map the existing literature on psychedelic drugs as modulators of social cognition in patients with psychiatric and neurodevelopmental disorders. The protocol follows JBI Scoping Review Methodology Group guidelines and will search MEDLINE, PsycINFO, EMBASE, and Scopus, with two-stage screening by two independent reviewers. The goal is to identify what is currently known and any gaps in the literature, potentially leading to new treatments for social cognition defects in clinical populations.

Study at a glance

Abstract

BACKGROUND: Impairments in social cognition are known to be a key factor in several psychiatric and neurodevelopmental disorders. Interest in psychedelic drugs has increased in recent years, with significant research identifying psychedelic and hallucinogenic drugs as modulators of social cognition. However, more research is necessary before psychedelics are implemented in clinical settings as treatments for social cognition defects. Therefore, this study describes a scoping review protocol which will be used to analyze the body of literature on psychedelic drugs as modulators of social cognition in patients with psychiatric and neurodevelopmental disorders. METHODS: This scoping review protocol was developed using the JBI Scoping Review Methodology Group's description of how to conduct a scoping review. The guidelines identified by this group as well as a search strategy developed with the assistance of a research librarian will be applied to a search of several peer-reviewed journals, including MEDLINE (Ovid), PsycINFO, EMBASE (Elsevier), and Scopus (Elsevier). Each study extracted will be screened in a two-step screening process, including a title and abstract screen, and a full-text screen. One independent individual will complete both steps of the screening, and a second independent individual will review the completed screening. DISCUSSION: An understanding of the current literature on psychedelic drugs as modulators of social cognition will provide insight into what is presently known on the subject, and any gaps in the literature that can be addressed in future studies. The knowledge gained from this scoping review could lead to a new treatment for social cognition defects in clinical populations.